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Chlorotriazines are widely used in agriculture as broadleaf herbicides. The compounds specifically inhibit photosynthesis, and, as such, display little
interaction with animal systems. However, a 24-month feeding study with atrazine (ATR) revealed a significant dose-related increase of mammary
tumors in female Sprague-Dawley (SD) rats. Because numerous studies indicated that ATR had a low mutagenic and oncogenic potential, it was
decided to test a hypothesis that the herbicide possessed endocrine activity. Among tests for estrogenic action, oral dosing of ATR up to 300 mg/kg
did not stimulate uterine weight of ovariectomized rats. However, ATR administration did reduce estrogen-stimulated uterine weight gain. Further
evidence of inhibition came from measures of [3H]-thymidine incorporation into uterine DNA of ATR-treated immature rats. Again, no intrinsic estro-
genic activity was observed up to a 300-mg/kg dose. In vitro, ATR competed poorly against estradiol binding to cytosolic receptors, with an approxi-
mate IC50 of 10-5 M. Atrazine administration to SD and Fischer-344 (F-344) rats for 12 months, up to 400 ppm in food, was correlated with
significant alterations of estrous cycling activity; but there was a divergent strain response. SD rats showed an increased number of days in vaginal
estrus, increased plasma estradiol, and decreased plasma progesterone by 9 to 12 months of treatment. F-344 rats rdid not demonstrate treatment-
related affects. A study of ultrastructure in the hypothalamic arcuate nucleus of female SD rats that were fed diaminochlorotriazine (DACT), an ATR
metabolite, suggested that age-associated glial pathology was enhanced by treatment. It is proposed that antiestrogenic actions of ATR are able to
disrupt critical hormone-mediated functions at very high dose levels. In SD rats, this disruption delays ovulation, maintains estrogen secretion from
ovarian follicles, and produces a hormonal milieu more conducive to mammary tumors. Aging in F-344 rats promotes higher progesterone secretion,
and it is predicted that mammary tumors would not be increased in ATR-fed F-344 animals. It is also concluded that the risk of ATR-related mam-
mary tumors in humans would be quite low because of the unique response of the SD rat estrous cycle, the nature of stimulated mammary tumors
in rats, and the extremely high dose levels and concentrations required for ATR to express activity in vivo and in vitro. -Environ Health Perspect
102(Suppl 11):29-36 (1994)
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Introduction
Atrazine is a major agricultural herbicide
that has been used in the United States and
other countries worldwide for over 25
years, primarily for control of broadleaf
and grass weed growth around corn and
sorghum crops (Figure 1). The herbicide
was developed and patented by CIBA-
GEIGY in 1958, and since the patent expi-
ration in 1975, has been manufactured and
sold by other companies as well. Atrazine is
This paper was presented at the Workshop on
Pharmacokinetics: Defining the Dose for Risk
Assessment held 4-5 March 1992 at the National
Academy of Sciences in Washington, DC.
The studies reported in this manuscript were sup-
ported in part by funding from the CIBA-GEIGY
Corporation, Agricultural Division. The authors grate-
fully acknowledge the excellent technical assistance
of Pamela J. Extrom and D. Scott Hill.
Address correspondence to Dr. J.C. Eldridge,
Department of Physiology and Pharmacology,
Bowman Gray School of Medicine, Wake Forest
University, Winston-Salem, NC 27157-1083.
Telephone (910) 716-8570. Fax (910) 716-8501.
a chlorinated member ofa family ofs-sub-
stituted triazines that selectively inhibit
electron transport systems in plant photo-
synthesis (1). The K, for atrazine in
chloroplasts has been reported as 1.4 x
i0-7 M by a mechanism believed to involve
direct, competitive inhibition of an elec-
tron carrier substrate (2). Because of this
specificity, reaction with animal systems
has not been reasonably suspected, and
indeed, effects at concentrations of 10-7M
have never been reported for test animals
or humans. For example, the oral LD50 in
rodents is approximately 3000 mg/kg (JO
Kuhn, unpublished data), which calculates
to 2 x 10-2 M ifthe substance were equally
distributed in total body water. (If 1 kg of
animal tissue contains 700 ml water, and
the formula weight [FW] for atrazine is
216: 3000 mg/700 ml=4286 mg/l = 19.84
mmole/l= 1.984x 10-2 M.) Nevertheless, a
concern regarding potential risk to humans
exists for manufacturing employees,
agricultural workers, and to the general
population through crop residue and
groundwater exposure.
Atrazine has been tested for mutagenic
potential in more than 50 studies ofgene
mutation, chromosomal aberration, and
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Figure 1. Chemical structures of two chlorotriazine
herbicides and a common metabolite.
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primary DNA damage, and a weight-of-
evidence evaluation indicates a nonmuta-
genic status relative to conventional health-
effects-testing formats (3). However, a life-
time feeding study revealed a dose-related
increased incidence of mammary tumor
formation in atrazine-fed female Sprague-
Dawley (SD) rats. Lifetime studies ofmale
rats, or of male or female mice, did not
result in increased tumors (4).
Mammary tumors are not an unusual
finding in aged SD female rats. In four sep-
arate 24-month atrazine-feeding studies,
the incidence ofadenocarcinoma in vehi-
cle-fed control female rats ranged from 17
to 40% (5). In a frequently cited study on
the appearance of tumors following expo-
sure to color dyes, the incidence of mam-
mary adenocarcinoma in 35 vehicle-treated
groups ranged from 0/70 to 26/62 (42%)
(6). Thus, it appears that background
noise for this parameter, in this rat strain,
at old age, can be substantial and variable.
Indeed, two of the four above-mentioned
feeding studies ofatrazine failed to demon-
strate a significant increase ofadenocarci-
noma when compared to each experiment's
own control incidence (5).
Mammary tumors in albino rats are
strongly hormone dependent. It has been
known for many years that the presence of
estrogens and/or prolactin promotes tumor
growth, while inhibition or removal of
either hormone results in tumor regression
(7-9). It is likely that the appearance of
mammary tumors in senescent female SD
rats is at least partially a result of lifetime
exposure to an endocrine environment that
promotes tumorigenesis, and that most, if
not all animals would eventually demonstrate
the lesions ifthey survived. An interesting
finding from the lifetime atrazine-feeding
study was that the incidence of mammary
tumors was not universal and peaked near
50% in the highest dosed animals. Many
well-known carcinogens in mammary tis-
sue, such as dimethylbenzanthracene
(DMBA) and N-methylnitrosourea (NMU),
typically induce tumors in 100% of the
subjects, and in a matter ofweeks follow-
ing a single dosing (10,11).
These observations suggested that an
administered agent that merely enhanced
tumor incidence from approximately one-
fourth to one-halfofthe animals might not
be a direct carcinogen as much as a modu-
lator ofendogenous hormone secretions,
serving to stimulate an earlier appearance in
a greater number of subjects. In effect,
atrazine could be promoting a premature
senescence ofreproductive and mammary
tissues. Therefore, studies were undertaken
to determine whether chlorotriazines pos-
sess endocrine-related bioactivities, and
whether chronic administration to test ani-
mals could induce senescencelike changes
in hypothalamic-pituitary-ovarian function.
Estrogen-Antagonist
Properties ofAtrazine
Despite the fact that lifetime feeding of
atrazine had not been associated with
mammary tumors in mice or in male rats,
it was nevertheless possible that chlorotri-
azines could possess a significant estrogenic
bioactivity that could promote tumor
growth in female SD rats. Consideration of
this possibility was appropriate to further
research because a number ofother chlori-
nated organic molecules (whose chemical
structures are not similar to estrogens) have
demonstrated estrogenic activity, and some
are indeed active pesticides (12,13). For
example, the insecticide dichlorodiphenyl-
trichloroethane (DDT) was extensively
studied and found to stimulate immature
rat uterine weight gain (14) and total RNA
and glycogen content (15), to competi-
tively inhibit estrogen binding to uterine
receptors (16), to translocate the estrogen
receptor complex into the nucleus (17),
and to promote uterine ornithine
decarboxylase in uterine tissue (18) and
progesterone receptor synthesis in rat
hypothalamic and pituitary tissue (19).
Methoxychlor, which is closely related in
structure to that of DDT, possesses much
the same hormonally active properties as
DDT after metabolism to more active
forms (18,20,21). Yet another chlorinated
insecticide, chlordecone (Kepone), whose
structure is quite distinct from DDT
analogs, as well as estrogens, also has been
reported to compete with estrogen binding
to its receptor in rat uterus (22,23), rat
hypothalamus (24) and chick oviduct
(25). Chlordecone stimulated rat uterine
weight (22,23), synthesis ofprogesterone
receptor (23), secretion of pituitary pro-
lactin and inhibition of luteinizing hor-
mone (LH) (26), masculinization of the
hypothalamus ofneonatal female rat pups
(27), and albumin synthesis in treated
chickens (25), all ofwhich are recognized
biological properties ofestrogens. In addi-
tion, other investigators have studied
chlorotriazine interactions with male repro-
ductive and endocrine function and have
found inhibition ofandrogen metabolism
and androgen receptor binding in rat pitu-
itary and prostate (28,29). Therefore, it
was considered a critical first step in our
research to determine the possibility of
estrogen expression by atrazine.
Tests of Uterine Weight
Stimulation
Two experiments were conducted on
ovariectomized adult female rats. In one
study, the animals were given atrazine by
gavage, in a vehicle ofcarboxymethylcellu-
lose (CMC) and water, at doses of0 (vehi-
cle only), 20, 100, or 300 mg/kg/day. After
3 days of treatment, the animals were
sacrificed and uteri weighed. As shown in
Figure 2, uterine wet weight was not
increased over control levels by atrazine
doses as high as 300 mg/kg (10% of the
LD50). An identical result has been
observed following treatment with
simazine or DACT, a common animal
metabolite ofboth herbicides (30). When
another set of ovariectomized rats was
administered atrazine by gavage and con-
comitantly injected sc with 2 pg estradiol
daily, an inhibition of uterine weight was
observed. The level of estrogen-induced
stimulation was reduced 13.6 and 23.2%,
respectively, by dosing with 100 and 300
mg/kg atrazine. Similar results have been
obtained after dosing with simazine and
with DACT, and at the same dose levels
(30). Thus, atrazine demonstrated estro-
gen antagonism, and only at a high dose,
with no sign ofagonist activity.
These experiments, although fairly sim-
ple in design, produced three important
findings. First, they suggested that chloro-
triazines do not possess the estrogen bioac-
tivity so frequently demonstrated for
DDT, chlordecone, and other chlorinated
pesticides described above. For example, 20
mg/kg o,p'-DDT was reported to stimulate
immature rat uterine weight 84% by 18 hr
postinjection; 120 mg/kg stimulated uter-
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Figure Z Uterineweight responses ofovariectomized rats
thatwere fed atrazine bygavage. Animals were dosed for
2 days, injected once with estradiol (E2) on the second day
and uteri were dissected and weighed 24 hr later.
Histograms represent means± standard errorofthe mean
(SEM) of six animals per dose. When no E2 was given,
uterine weights were not differentfrom vehicle-gavaged
control. When one E2injection was given, a significant(1-
wayANOVA, p= 0.0001) dose-related suppression was
seen. Asterisks (*) indicate group means significantly dif-
ferentfrom mean uterineweightofcontrolsgiven E2with-
outatrazine(Bonferroni'spost-hoctest, bothp<0.02).
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ine weight more than 4-fold (15). Second,
a significant antagonist property ofatrazine
was observed, suggesting that the herbi-
cides may indeed possess an endocrine-
related activity of interest. Third, effects
were observed only at very high doses of
administration (i.e., 100 mg/kg and
above). The appearance of mammary
tumors also has been associated only with
feeding levels above 70 ppm atrazine,
which was calculated by CIBA-GEIGY
to be about 5 mg/kg bw.
Inhibition ofThymidine
Incorporation into Uterine
DNA
Following demonstration that atrazine could
retard estrogen-stimulated uterine weight
growth, it was decided to examine this prop-
erty in a morespecific way, as in atesting sit-
uation, uterine weight increase could be
impacted by numerous nonendocrine fac-
tors. Indeed, the animals dosed with atrazine
in the uterine weight study had lost total
body weight in a dose-related fashion.
Therefore, a measure ofuterine DNA syn-
thesis was taken, because it occurs prior to
tissue growth, and because increased synthe-
sis has been shown to correlate highly to the
amount ofbioactive estrogen present (31).
In this study, intact, immature female rats
were purchased before weaning and used at
23 days of age. Each animal was gavaged
once daily for 2 days with atrazine in CMC
vehicle at doses from 0 to 300 mg/kg. On
the second day, each animal also received
0.15 pg estradiol sc in saline. Animals were
sacrificed 24 hr after the estradiol injection,
and the uteri were dissected. Using a proto-
col of Stormshak et al. (322, tissues were
sliced and incubated with [ H]-thymidine
for 60 min at 37°C. DNA was extracted
from the incubated slices, quantified, and
counted byliquid scintillation ofasample.
As shown in Figure 3, incorporation
rate was significantly inhibited in animals
administered 50, 100, or 300 mg/kg
atrazine, but not inhibited in animals given
1 or 10 mg/kg. Furthermore, animals given
300 mg/kg atrazine without the estradiol
injection showed an incorporation rate
lower than that of estrogen-injected ani-
mals given 300 mg/kg, or than that ofthe
vehicle-treated controls. This result indi-
cated that in the same dose range which
inhibited uterine weight growth atrazine
also reduced an estrogen-specific early
step-namely, DNA synthesis. Additional
studies with simazine or the metabolite
DACT have produced identical results,
(30) suggesting that the active principle for
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Figure 3. Incorporation (cpm/pg DNA) of [3H]-thymidine
into DNA extracted from uteri of rats that were adminis-
tered atrazine by gavage. A total of 114 animals were
used, at 23 days of age; each symbol represents the mean
± standard error of mean (SEM) of 7 to 26 animals per
treatment group. Asignificant(1-wayANOVA, p<0.0001)
dose-related inhibition was observed; mean values at 1
and 10 mg/kg were not different from the mean value of
animals given estradiol alone; mean values at 50, 100, and
300 mg/kg atrazinewere significantly lowerthanthe mean
forthe group given E2alone(all p<0.01, Bonferroni's post
hoctest). In addition, the mean incorporation rate in a
group given atrazine alone (no E2) was significantly lower
than the mean of untreated control animals (p< 0.05),
Bonferroni'sposthoctest). SeetextandTennantetal. (30)
foradditional details ofthestudy.
inhibition of estrogen activity may be a
didealkylated metabolite rather than the
herbicide itself.
Atrazine Interactions with the
Estrogen Receptor
Following demonstration that atrazine
administration was antagonistic to estrogen
expression in a rat uterine model, it was
necessary to determine whether this antag-
onism could be exerted through competi-
tive suppression ofestrogen binding to its
receptor (ER). It is generally accepted that
expression of many steroid hormone
actions begins with binding ofligand to an
intracellular protein, which then associates
with the genome ofthe target cell to initi-
ate transcription of specific messenger
RNAs. In the case ofestrogens, binding to
ER is a crucial first step for many agonists
and antagonists, and indeed, the above-
cited agonist effects of many chlorinated
pesticides have been associated with bind-
ing ofthe chemicals to ER (16,22-24 ).
Uterine tissue from adult SD rats was
dissected, homogenized inTris-EDTA-glyc-
erol buffer, and cytosol was prepared (33)
and incubated at 40C overnight with [3H]-
estradiol plus or minus atrazine or unla-
beled estradiol. Under these conditions it
was not possible to demonstrate any com-
petition for estradiol binding to ER in the
presence of atrazine, at concentrations up
to 10 M (34). In no case could competi-
tion be observed under any condition of
concomitant incubation ofsteroid and her-
bicide, or under conditions leading to equi-
librium. However, competition was
demonstrable under a nonequilibrium con-
dition (Figure 4) and as described below.
When cytosol was incubated with
atrazine for 30 min at room temperature,
then cooled in ice, and radiolabeled estra-
diol was added, a clear inhibition ofsteroid
binding was observed. Figure 4 shows the
effect ofpreincubation with atrazine at 0.1
mM, but inhibition was demonstrable with
simazine and DACT as well, and at lower
concentrations (34). Approximate IC50
calculations were made for all three com-
pounds in the range of 10-5 M, versus an
IC50 of 10-1 M for estradiol. Although this
concentration of chlorotriazine might
appear unreasonably large for expression of
relevant biological action, the level is in
line with the in vivo dosing range of our
studies described earlier: 300 mg/kg, dis-
tributed equally in 700 ml of total body
water, is approximately 2 x 10-3 M. An
intracellular concentration of 10-5 M for a
small lipophilic molecule such as atrazine,
or a metabolite in a test animal continu-
ously fed 500 ppm for a lifetime does not
seem unreasonable.
Scatchard analysis was conducted by
incubation of radiolabeled estradiol and
ER in the presence of unlabeled estradiol
or atrazine (Figure 5). As before, the results
were obtainable only by preincubation of
competitor for 30 min at 250C, followed
by 60 min of [3H]-estradiol at 40C. By
comparison with the Scatchard plot for
excess unlabeled estradiol, the plot for
atrazine displacement had both a lower
slope and a slightly reduced Bmax" suggest-
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Figure 4. Competition of atrazine against [3H]-estradiol
binding to uterine cytosol. Tissue was prepared by
homogenization of intact rat uteri and centrifugation at
105,000g for 60 min. Note that cytosol was incubated
with 0.1 mM atrazine for 30 min at 25°C, then put on
ice, prior to addition of radioligand. Each point repre-
sents the mean of triplicate tubes; incubations were
stopped at 8 points between 5 and 150 min after addi-
tion of tracer. Additional details of the methodology
appear in the textand Tennant etal. (34).
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Figure 5. Scatchard plots of [3H]-estradiol binding to uter-
ine cytosol in the presence of 100-fold molar excess unla-
beled E2(0) or 10,000-fold molarexcess unlabeled atrazine
(1). Cytosol preparation and incubations conducted as
described in text and in the legendto Figure 4. Itshould be
emphasized that competition or a Scatchard plot could be
generated for atrazine only ifthe herbicide were incubated
with cytosol for30 min at25°C prior to addition of radiola-
beled E2 at 4°C. Furthermore, no competition appeared
under any condition with 100-fold excess unlabeled
atrazine. For the E2 plot: KD = 0.46 nM, Bmax= 68.5
fmole/mg protein, r= 0.979. For the atrazine plot: K0 =
0.88nM, Bmax =53.4fmole/mg protein, r=0.971.
ing the possibility ofsome competitive and
noncompetitive inhibition by atrazine.
Thus, atrazine was able to interact with
ER binding ofestrogen, but the nature of
the interactions appeared weak and occurred
only at very high concentrations. Under
equilibrium conditions, no competition of
atrazine was evident, suggesting that the her-
bicide might be able to interfere only ifit
were present at elevated levels and prior to
exposure ofthe target cells to estrogens. In
fact, such conditions were present during
both ofour studies on uterine weight stimu-
lation and thymidine incorporation
described earlier, and the condition could
theoretically exist during certain periods of
diestrus in a continuously fed, cycling
female rat, when ovarian estrogen secretion
is at an ebb.
The results of all of the studies
described to this point suggest further that
a threshold for estrogen antagonist expres-
sion by atrazine in rats is found in the
dosage range of 50 to 100 mg/kg for oral
administration, and a concentration range
10-5 M for interaction with uterine estro-
gen receptors. In all of our studies on sev-
eral chlorotriazine compounds, whether by
oral dosing or by incubations in vitro, we
have never observed any actions to occur at
levels lower than the 10-5M range. These
observations are particularly relevant when
considering human risk because they sug-
gest that, insofar as these endocrine actions
are concerned avoidance ofexposure to lev-
els in excess of 50 mg/kg/day, or of intra-
cellular concentrations greater than 10-5M
should provide an environment free of
related adverse effects.
Long-Term Effects ofAtrazine
on Estrous Cycling and
Reproductive Hormone
Secretion of Female Rats
While research focusing on elucidation of
mechanisms for an estrogen antagonist
action by atrazine remains an important
goal, it also becomes necessary to consider
how an enhanced incidence of mammary
tumors in senescence could derive from
chronic administration ofa weak antiestro-
gen to test animals. Preliminary results
from studies conducted by CIBA-GEIGY
indicated that female rats, when fed
atrazine at doses of 100 ppm and greater,
displayed abnormal and irregular estrous
cycling patterns. Our laboratory conducted
a 2-week study ofSD female rats that were
administered atrazine by gavage at 100 and
300 mg/kg/day (35). Results showed that
estrous cycling became significantly length-
ened and less regular in atrazine-treated
animals, with additional days ofestrus. The
experimental design was repeated in F-344
rats, which also displayed fewer abnormal
estrous cycles with atrazine dosing. When
occurring, the additional days ofthe F-344
estrous cycles were in metestrus/diestrus
rather than in estrus. Because SD female
rats are known to enter transient periods of
constant estrus with advancing age, while
F-344 animals have a greater tendency to
increased days in pseudopregnancy with
aging (36,37), it was proposed that a simi-
lar divergence of strain response might be
occurring with chronic atrazine dosing. In
concurrent, long-term atrazine feeding
studies (one used SD female rats, the other
F-344 females), estrous cycling patterns
were monitored and blood samples were
collected throughout the studies. As this
manuscript was being prepared, data had
been analyzed through the first year ofa 2-
year dosing schedule, and those results are
presented here. Additional results from
these studies have also been published
(38).
Estrous Cycling and Vaginal
Cytology Characteristics
Three groups of70 SD female rats were fed
0, 70, or400 ppm atrazine; five groups ofF-
344 animals were fed 0, 10, 70, 200, or 400
ppm atrazine. A set of 10 animals ofeach
strain and feedinglevel was sacrificed at 1, 3,
9, or 12 months offeeding and trunk blood
was collected. Vaginal smears were prepared
and read daily for 14 to 20 days prior to
sacrifice, and animals were sacrificed on the
dayofproestrus, when possible.
SD female rats showed a significant
trend in an increased number ofestrus days
both with aging and dosing (p<0.01),
while F-344 rats did not (Figure 6). In par-
ticular, SD rats that were fed atrazine for 9
months at 400 ppm demonstrated nearly
twice as many days in vaginal estrus, on
average, as their cohorts of the same age
that were fed vehicle, or than SD rats that
were fed the same 400 ppm dose for 3
months. By 12 months of feeding, the
vehicle-control rate of estrus had risen to
the level seen with 9 months of400 ppm
feeding, but the level in 12 months, 400-
ppm animals had continued to rise. By the
12th month, the occurrence of estrus in
SD rats had now risen from about one per
five-cycle day to nearly three per 5 days,
while in F-344 females, the occurrence of
estrus held steadywith dosing.
This finding was substantiated by addi-
tional analyses of the types of epithelial
cells on the vaginal smear slides (data not
presented here). Results showed that the
density of cornified epithelial cells, which
represents overall estrogen bioactivity in
the animal, rose steadily in direct relation
to dose and advancing age in SD rats; in
1 mo. 3 mo. 9 mo. 12 mo.
Figure 6. Percent of total estrous cycle days judged as
estrus in two rat strains fed atrazine continuously for
12 months. Histograms represent mean ± SEM of 10
animals on whom vaginal smears were prepared for 15
to 20 consecutive days at each sampling time. Doses,
in ppm, are indicated by numbers inside the histograms
for 1 month/dosing. For the SD strain, a two-way
ANOVA revealed significant effects of dosage (p =
0.026), time (p< 0.0001) and a dose x time interaction
(p= 0.012). Within the 9- and 12-month sampling times
a significant effect of dose was observed (p= 0.002, p
= 0.039, respectively). No significant overall effects of
dosage or time were observed for this parameter in
Fischer-344 rats.
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F-344 animals, cornified cell density was
elevated only at 12 months of treatment,
and then equally for all dosing groups. The
density of nucleated epithelial cells,
another vaginal cell type that correlates
more closely to overall progesterone bioac-
tivity, was unchanged with dose or time in
the SD animals, and was increased with
time only in treated F-344 subjects (no
dosing effects). Thus, it was apparent that
atrazine dosing had altered estrous cycling
activity in a way that caused increased
estrogen production in SD but not in F-
344 rats. The SD animals appeared to have
an age-related trend in that direction,
which became advanced or accelerated by
atrazine feeding.
Estradiol and Progesterone
Levels in Atrazine-fed
Female Rats
Plasma samples obtained at sacrifice from
the sets of 10 animals in each treatment
group were analyzed for estradiol and prog-
esterone by radioimmunoassay (RIA) pro-
cedures. As predicted from examination of
vaginal cytology, responses of the two rat
strains were quite dissimilar (Figure 7).
In SD animals, plasma estradiol demon-
strated a marked dose-related increase, par-
Plasma Progesterone
Figure 7. Plasma estradiol (E2) and progesterone (P4) in
two rat strains fed atrazine continuously for 12
months. Samples were collected at sacrifice on a day
of vaginal proestrus, when possible. Hormones were
measured by solid-phase radioimmunoassays
(Diagnostic Products Corporation, Los Angeles, CA). For
plasma E2 in Sprague-Dawley (SD) rats, a significant
effect of dosage (p = 0.033) but not duration was
observed; in Fischer-344 (F-344) rats, a significant
effect of duration (p = 0.009) but not dosage was
observed. For plasma P4, a significant overall decrease
with duration was observed for SD rats (p = 0.016),
and a significant increase was observed for F-344 ani-
mals (p = 0.026). No treatment-related effects were
observed for either hormone in either strain; no
dosage-time interactions were observed.
ticularly at 400 ppm (p<0.01), and F-344
animals also displayed a rise of plasma-
estradiol levels in relation to increasing age,
but not to dosing. Plasma progesterone lev-
els decreased with advancing age in SD rats
and increased with age in F-344 animals.
Plasma-estradiol and progesterone changes
at 12 months of age were particularly
notable in both strains when each was com-
pared to levels at 9 months of age.
However, neither strain showed a
significant trend to change plasma-proges-
terone as a function ofdose. Plasma-pro-
lactin was not elevated in either strain in
relation to age or treatment dose (data not
shown), which supports a conclusion that
prolactin, which can stimulate mammary
tumor growth in rats (7-9), was not a
likely factor in tumorigenesis associated
with chlorotriazine administration.
Overall, the effect oflong-term atrazine
dosing appeared to be a dose- and age-
related increase in estrogen levels relative to
progesterone, in SD rats. In F-344 rats,
however, estrogen levels held steady, or
even fell relative to progesterone, and only
in the more aged subjects. No significant
treatment effects appeared in the F-344
animals. These overall results represent a
substantial strain-related divergent
response to oral feeding of identical
amounts of atrazine, and both responses
appeared similar to those normally demon-
strated by each strain with advancing age
(36,37). The most noteworthy aspect of
these divergent responses is that the SD
rats, which developed an increased internal
estrogen environment relative to proges-
terone, were the strain in which mammary
tumors also appeared. F-344 animals devel-
oped an internal environment that favored
progesterone relative to estrogen.
Progesterone is known to reduce or retard
mammary tumor formation in rodents
(7-9), and this suggests a mechanism
whereby F-344 rats would respond to
atrazine feeding with no enhancement of
mammary tumor development.
A second noteworthy overall result was
the relative absence of responses in
endocrine secretion and control of estrous
cycling through the first 3 months oftreat-
ment. Our earlier 2-week studies had pro-
duced significant changes in both estrous
cycling and reproductive steroid levels, but
these experiments were conducted by gav-
age of 100 and 300 mg/kg once a day,
which exceeded the maximum tolerated
dose. The chronic, 1-year feeding studies
were conducted by mixing atrazine into the
diet, up to 400 ppm, and the animals were
not experimentally handled except for
preparation ofvaginal smears. However,
even these high levels ofadministration (up
to 0.04% of total food intake) resulted in
measurable changes ofthe parameters stud-
ied only after a significant lag time; perhaps
a substantial accumulation ofagent is nec-
essary or the metabolic alteration of
atrazine may be an important step. As
described earlier, DACT, the didealkylated
metabolite (Figure 1), contains estrogen
antagonist activity at a similar dose to that
ofatrazine itself(30).
The chronic 1-year feeding studies
demonstrated that ovulatory cycling is dis-
rupted in animals fed atrazine. It is difficult
to couple this finding mechanistically with
our previously observed estrogen-antago-
nist properties, given our present knowl-
edge. It might be concluded that atrazine
(or a metabolite) inhibits an estrogen-
dependent process necessary for prompt
ovulation and regular estrous cycling, but
such a specific process is not easily
identifiable. The neuroendocrine control of
ovulation is a delicate balance ofsteroids,
pituitary gonadotropins, hypothalamic
neuropeptides, and central neurotransmit-
ters, plus environmental factors. The pre-
cise reason for strain-related divergence of
estrous cycling patterns in aging SD versus
F-344 rats is also not known, so it remains
to be elucidated how an antiestrogenic
action on the part ofthe herbicide can be
translated into the same final result
through different target sites.
Ultrastructural Changes in
Arcuate Nucleus with
Chlorotriazine Feeding
The rat hypothalamus controls ovulation
through secretion ofregulatory hormones
that control release of pituitary gonado-
tropins, which in turn stimulate ovarian
function. One of the focal hypothalamic
areas ofreproductive control is the arcuate
nucleus: lesions or isolation ofthis nucleus
in female SD rats causes the arrest ofestrus
cycles in the estrus (36), and it has long
been proposed that reproductive aging in
female SD rats begins with deterioration of
function at this site (36). Some years ago,
ultrastructural examination of arcuate
nucleus tissue from aging SD female rats
revealed the presence of dendritic and
axonal degeneration, and astrocytic and
microglial reaction (39). This picture of
neuropathological change had actually
been observed earlier in estrogen-treated
young female rats, which also had devel-
oped a persistent vaginal estrus (40) and
inability to generate preovulatory LH
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surges (41). It was suggested that continual
estrogen exposure advances the aging
process by inducing pathologic change in
the hypothalamus. We investigated by elec-
tron microscopy the possible role of
chlorotriazine administration through
examination ofhypothalami from female
rats that were fed DACT (42).
As shown in the example in Figure 8,
astrocyte inclusion granules increased in
number with aging (20 versus 48 weeks),
and granule number increased even further
in 48-week-old rats that were fed 1000
ppm DACT beginning at 20 weeks ofage.
By group analysis, astrocyte granule-density
of48-week-old untreated controls increased
56% over the 20-week level (p < 0.01),
while density of DACT-fed, 48-week-old
animals was increased another 48% over
age-matched controls (p < 0.05). This
increase ofglial reactivity in the same direc-
tion as normal aging suggests that the arcu-
ate nucleus of the DACT-treated animals
had aged at a faster rate than normal.
Because we have already established that
SD female rats fed chlorotriazines produced
significantly more estrogen (Figure 7), it
seems possible that atrazine-fed female rats
developed irregularity of cycling and
episodes ofconstant estrus because ofestro-
gen toxicity in the hypothalamus.
It should also be mentioned that arcu-
ate nucleus lesions induced by high doses
of estradiol administered to young rats
were substantially blocked if the animals
were ovariectomized (43). In addition,
constant low-dose estrogen administration,
even to ovariectomized rats, enhances arcu-
ate nucleus gliosis (44). These findings
suggest that "toxic" events early in life can
have persistent effects, if the subjects con-
tinue to secrete estrogen, and that contin-
ual estrogen secretion is equally important
for more complete neuropathology to
develop. This would support a concept
that, in long-term, atrazine-treated SD rats,
the early effects of dosing may be vitally
important in initiating a chain of events
that culminate in an increased incidence of
mammary tumors. Endogenous hormone
levels are likely to be lower during the time
of actual tumor growth, so the environ-
ment in senescence, while possibly
involved in tumorigenesis, nevertheless
maybe secondary to events earlier in life.
Summary and Conclusions
When presented with the observations that
SD female rats that were fed a substantial
quantity ofatrazine dailyfor a lifetime devel-
oped a significant (but not ubiquitous)
increase of mammary cancer, that other
rodent strains and species did not form these
tumors after atrazine feeding, and that
numerous tests ofmutagenicity were nega-
tive, it became logical to propose that the
herbicide could be exerting a hormonelike or
endocrine-modulatory action in the test ani-
mals. Other compounds, particularly chlori-
nated pesticides, are known to be estrogenic,
and although atrazine structure does not
resemble that ofestrogens, the possibility of
adirect interaction seemed reasonable.
It was found that atrazine, when pre-
sent at very high levels in vivo or in vitro,
can exert an apparent antiestrogenic effect.
A variety oftest modalities, including uter-
ine weight, thymidine incorporation into
DNA, and estrogen receptor binding, sug-
gest that atrazine, as well as simazine and
the common metabolite DACT, can
inhibit or reduce estrogen-stimulated activ-
ity in target areas. None of the tests sug-
gested that chlorotriazines have estrogen
agonist activity, or a hormone-stimulatory
activity ofany kind. To our knowledge, no
other chemical has been shown to possess
this constellation ofactions.
When administered by gavage or in
food, atrazine induced significant disrup-
tions ofnormal estrous cycling in two dif-
ferent rat strains, and the respective
responses also were different. A hypothe-
sized view of these alterations is illustrated
in Figure 9. Atrazine-treated SD animals
appeared to delay the succeeding ovulation,
as indicated by the increased number of
days in vaginal estrus. The response was
likely due to arrested development of
mature ovarian follicles which, when com-
bined with plasma-hormone data, suggests
that the treated animals existed in an ele-
vated estrogen environment.
It is significant that the respective rat
strains each undergo alterations ofestrous
cycling with aging, but we propose that
atrazine administration resulted in an
advancement or enhancement ofthe repro-
ductive aging process in SD rats. The study
of hypothalamic ultrastructure provides
supporting evidence for this conclusion.
The specific mechanism by which atrazine
is able to accomplish this effect may lie in
understanding the nature of reproductive
aging in the respective strains. It is possible
that the herbicide is able to inhibit or
reduce to a critical degree some function(s)
involved with the ovulatory cycle that are
estrogen-dependent. In SD rats, the essen-
tial result would be an augmented estrogen
Figure 8. Representative sections showing astrocytes in the arcuate nucleus of female rats that were fed lab
chow containing vehicle at ages 20 weeks (A) or 48 weeks (B), or 1000 ppm diaminochloroatrazine (DACT) until
age 48 weeks (C). Feeding was begun at 20 weeks of age. Note the increase of astrocytic granules with advanc-
ing age (A compared to B), and the additional increase in a DACT-treated animal (Bcompared to C). See text and
Tennant et al. (42) forfurtherdiscussion of group results. Magnification xl950.
Figure 9. Proposed mechanism by which atrazine
administration could interact with rat estrous cycling
control to support an environment-enhancing mammary
tumor formation. Note the divergent responses of the
Sprague-Dawley(SD) versus Fischer-344 strains.
Environmental Health Perspectives 34HORMONAL EFFECTS OF TRIAZINE HERBICIDES INFEMALERATS
environment and stimulation ofmammary
tumor growth later in life; F-344 rats, with
augmented progesterone secretion, would
not be as likely to develop the tumors. Our
basic conclusion, therefore, is that atrazine
administration does not actually induce
new tumors, but rather that a normal rate
oftumor appearance is shifted to an earlier
time in life through manipulated hormone
secretion.
The critical time for stimulation of
tumor formation may not be during old
age, but the midage of 9 to 18 months.
After this time, ovarian steroid output falls
precipitously and a state of constant
diestrus ensues. Indeed, the often-studied,
tumor-inducing agents such as DMBA and
NMU lose effectiveness when administered
past 90 days of age (8-11): Therefore, if
mammary tumor growth in senescence
may be promoted by a hormone environ-
ment that existed earlier in life, the effect of
an administered agent during the first half
of life may be most critical. There are, of
course, other possible reasons why mam-
mary tumors appear in treated animals,
among them being direct alterations of
steroid hormone synthesis, metabolism, or
clearance. The herbicides could also exert a
variety ofnonendocrine actions working in
concert with hormone alterations.
Possible Significance
for Human Risk
It is always difficult, and perhaps not even
appropriate, to attempt to interpret results
from animal research in direct terms ofrisk
assessment for humans. However, the pre-
sent studies have yielded a number ofresults
that might be useful to those concerned
with safety and hazards of agricultural
chemicals. We observed a variety ofeffects
that pointed to disruption ofreproductive
cycling and hormonal activity in atrazine-
treated rats, but the required doses had a
definite threshold in the range of50 to 100
mg/kg/day and 0.01 mM. Numerous doses
and concentrations below these levels did
not elicit responses, and one may conclude
that human exposure below the same levels
would be similarly ineffective. On the basis
ofour findings, it is extremely likely that
exposure to trace amounts ofatrazine would
yield no effect whatever on the parameters
tested. It should be emphasized that the
estrous cycling changes we observed did not
appear until after several months ofcontinu-
ous exposure, suggesting that occasional
exposure even to high atrazine levels might
be tolerated easily. An increased rate of
mammary tumor formation resulting from
our proposed mechanism would likely
require a continuously altered hormone
environment, which in the case ofhumans
is manyyears.
Atrazine is metabolized in mammals
principally by dealkylation of the amino
groups (Figure 1), and we have observed
basically similar biochemical effects of one
principal metabolite, DACT, as with
atrazine itself. Studies in humans have
shown that metabolism proceeds in much
the same manner as in rodents (45), except
that SD rats tend to sequester metabolites
in their erythrocytes (46). This results in a
two-compartment model ofelimination of
the metabolites, and a slower rate ofclear-
ance from rats than humans (IWF
Davidson, unpublished personal communi-
cation). Therefore, one might surmise that
the rat model is more sensitive than other
species, including humans, to the hor-
mone-related effects we observed, because
metabolism and clearance in rats would
proceed at a slower rate.
Additionally, human menstrual function
is quite distinct from the rat estrous cycle,
particularly in relation to the mode ofaging
in each species. Rodents and many other
mammalian orders lose control of estrous
function by means ofneuroendocrine (neu-
rotransmitter/neurophysiologic) failure, so
that factors which disrupt or damage proper
neuroendocrine activity could be viewed as
contributing to the aging process. The
response, as we observed in SD rats, is a
delay ofovulation, persistent mature ovarian
follicles, and enhanced estrogen output dur-
ing mid age. Reproductive aging in women
seems to involve primarily the declining
population ofovarian follicles rather than
neuroendocrine disturbance. Indeed, recent
studies of the events ofprimate ovulation
appear to implicate a reduced role for critical
neuroendocrine control ofthe process (47).
This would suggest that human females in
particular would be less susceptible than
rodent females to an agent that disrupts
neuroendocrine control of ovulation.
Furthermore, menstrual cycles of middle-
aged women are characterized by decreased,
not increased, estrogen secretion (48).
Finally, one should consider what is
known about mammary cancer in women as
compared to rodents. The types oftumors
observed in senescent atrazine-fed rats were
quite different from those seen following
treatment with DMBA and other tumori-
genic materials (5). Indeed, the pathologic
picture of atrazine-associated tumors was
not different from that seen in age-matched
controls; there were simply more tumors
and more rats with tumors. Tumors that are
directly inducible in rats can be maintained
rather easily by estrogens and/or prolactin
secretion, as previously described. Tumors
in women are not so completely correlated
to endogenous hormone exposure; approxi-
mately one-half of human mammary
tumors are not estrogen-responsive because
they lack the intracellular estrogen receptor
necessary for expression ofhormone action
(9). Mammary cancer in women more indi-
rectly correlates to hormone exposure by
virtue of reports that, for example, women
who first bear children at a younger age
seem to be at reduced risk (9). Overall,
environmental influences seem to affect the
appearance ofhuman cancer less than do
inheritance and familial history. Therefore,
one may conclude that a significant risk of
mammary cancer in humans who are
exposed to atrazine and chlorotriazine herbi-
cides, while theoretically possible from a
variety ofsources that are not the subject of
our studies, is not supported by the present
experiments.
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